Endologix, Inc., incorporated in March 1992, develops, manufactures, markets and sells treatments for aortic disorders. The Company’s product, the Powerlink System is a minimally invasive device for the treatment of abdominal aortic aneurysm (AAA). AAA is a weakening of the wall of the aorta, an artery of the body. Once AAA develops, it continues to enlarge and if left untreated becomes susceptible to rupture. The Powerlink System is a catheter and endoluminal stent graft (ELG) system. The device consists of a self-expanding cobalt chromium alloy stent cage covered by expanded polytetrafluoroethylene (ePTFE), a surgical graft material. Sale of its Powerlink System in the United States, Europe, Japan and Latin America are the primary sources of the Company’s revenues.